We have compared the efficacy of daily injection of recomgiven as mean ± standard error of the mean.) Importantly, binant leptin protein (rh-leptin) with adenovirus-mediated rh-leptin and ex vivo-expressed Ad-leptin were equivalently delivery of the murine or human leptin gene (Ad-leptin) for active in a functional cell-based assay. The primary differtreatment of obesity in the obese (ob/ob) mouse model. ence in the two therapeutic approaches is the continuous We demonstrate an improved correction profile for obesity chronic secretion of leptin mediated by gene delivery, verand associated surrogate markers using the adenovirus sus the intermittent bolus delivery and rapid clearance of delivery method. Rate of weight loss and percentage satthe daily injection of rh-leptin protein. Thus, in vivo findings iety were significantly greater in the mice treated with Adsuggest that leptin effects are better achieved at lower leptin. These findings were associated with lower peak steady-state levels, a pharmacological feature attained serum leptin levels with Ad-leptin (22.9 ± 2.6 ng/ml for the here by gene therapy. These findings may have implihuman gene, and 48.9 ± 11.5 ng/ml for the murine gene) cations for the potential use of leptin in the treatment of compared to rh-leptin (385.2 ± 36.0 ng/ml). (Values are obesity.
Introduction
iety was provided by the obese (ob/ob) mouse model. Obesity affects 6-10 million individuals in the USA alone Leptin is undetectable in plasma of the ob/ob mice and is commonly associated with medical problems, such because of a nonsense mutation at codon 105. 12 Homozyas hyperlipidemia, hypertension, and diabetes type II.
gotes rapidly gain body weight and are recognized as Weight reduction in a large subset of patients results in early as 4 weeks after birth. 13 They are hyperphagic, substantial improvement in the associated medical probhyperglycemic, hypoactive, and have elevated plasma lems. Leptin has recently been identified as one of the insulin levels. 14 Daily recombinant leptin protein delivery factors controlling satiety. It is exclusively expressed in was shown to induce weight reduction, suppress appeadipose tissue and consists of 167 amino acids with an tite, and decrease blood insulin and glucose levels in 84% homology between human and mouse proteins. 1 these mice. 12, [15] [16] [17] [18] Leptin exerts its appetite-suppressive function through Protein injection is frequently used to treat peptide horbinding to its receptor in the hypothalamus, where it is mone deficiencies. Although leptin can be delivered in suggested that leptin enters the brain by a transport systhis way, the treatment is compromised by its short durtem that can be saturated.
2-5 Serum levels of leptin correation of action and the need for repetitive dosing. An late well with the body mass index of both children and alternative possible approach to recombinant protein adults, and bioactivity of leptin is influenced by its rate delivery is gene delivery. Adenoviral vectors are shown of production, half-life (24.9 ± 4.4 min), and clearance rate to be highly efficient vectors for delivering genes in a var-(1.5 ± 0.23 ml/kg/min). 6 The leptin receptor has been iety of tissues in vivo, with a natural tropism to the liver shown to be expressed in several tissues other than the when administered intravenously. [19] [20] [21] [22] To circumvent the hypothalamus, including primary rat pancreatic islets need for daily injection of recombinant leptin protein, we and the insulinoma cell line, beta TC-3. The binding of tested in vivo adenovirus-mediated leptin gene delivery leptin to beta cells suggests a potential role in modulation (Ad-leptin), and compared its efficacy in correcting the of insulin expression. [7] [8] [9] [10] Recent in vitro-based studies phenotype of the ob/ob mouse model with that of daily suggested that maintenance of high leptin levels may injections of recombinant leptin (rh-leptin). We report contribute to insulin resistance, resulting in obesityhere the unequivocal greater efficacy of Ad-leptin over associated diabetes. 11 rh-leptin, despite in vitro measured, equivalent activity of the proteins delivered by these two methods. 9 mg/kg. Samples measured 1 h after injection, at days 2 Results and 4 of rh-leptin treatment, were 267.7 ± 15.1 and 335.2 ± 52.9 ng/ml, respectively. As expected, rh-leptin Weight loss and satiety was cleared rapidly, with greater than 70 and 95% of the To compare the effects of in vivo gene-mediated leptin recombinant protein undetectable in the serum samples expression and recombinant leptin protein delivery on collected at 2 and 3 h after i.p. injection, respectively, and satiety and weight loss, 12-week-old ob/ob or lean mice could not be measured thereafter. The appearance of antiwere treated either with a single tail vein injection (1 × 10 9 leptin antibodies in the sera of treated mice within the plaque-forming units (p.f.u.) ) of adenoviral vectors first week of treatment interfered with the accuracy of expressing human (Ad-h-leptin) or mouse leptin (Ad-msubsequent enzyme-linked immunosorbent assay leptin), or with daily intraperitoneal (i.p.) injections (1 (ELISA)-based measurements. The average blood levels mg/kg) of recombinant leptin protein (rh-leptin). The measured at 1 h after rh-leptin treatment were ob/ob mice weighed on average 50 g; those receiving rh-137.58 ± 9.68 ng/ml (days 1-44). leptin were given 50 g protein per day as a constant
In lean animals treated with Ad-h-leptin and Ad-mdose throughout the length of the study. Controls were leptin, maximum plasma levels of leptin detected were injected with either rh-leptin buffer or adenoviral control 32.9 ± 6.3 and 36.1 ± 8.3 ng/ml, respectively; rh-leptin vector expressing the reporter gene ␤-galactosidase (Adlevels measured at 1 h after injection were 218.0 ± 19.9 ␤gal). Time-dependent weight loss is illustrated in Figure  ng /ml. 1a and b. The selected Ad-leptin and rh-leptin doses gave initial identical weight reduction profiles during the first In vitro activity 3 days of treatment. Subsequently, the time at which the Our in vivo studies suggested a significantly greater effiobserved maximum weight loss occurred was significacy of Ad-leptin over rh-leptin. It was therefore cantly earlier for ob/ob mice treated with Ad-h-leptin important to determine whether this difference was due and Ad-m-leptin, compared with those that received rhto protein modifications during eukaryotic expression of leptin (12.8 ± 0.9, 13.6 ± 1.0 and 40.5 ± 1.2 days after treatthe adenoviral gene, or relative inefficiency of the recomment, respectively). This maximum effect was obtained binant protein, which was expressed in a prokaryotic syswith a total administration of 10 9 p.f.u. or 2.2 mg rh-leptin tem. To address this issue, we tested the relative bioactivover 44 days. In ob/ob mice treated with Ad-h-leptin, ity of both proteins using an in vitro cell-based assay. The Ad-m-leptin or rh-leptin, maximum weight changes from rh-leptin activity was indistinguishable from that of Adbaseline in response to treatment were −22.3 ± 1.83% h-leptin, as measured by a leptin-responsive promoter (−11.1 ± 1.0 g), −27.9 ± 2.8% (−13.9 ± 1.6 g) and −22.9 ± driving a luciferase reporter gene ( Figure 3 ). The in vivo 1.86% (−11.5 ± 1.14 g), respectively. Ad-leptin treatment results therefore cannot be explained by differences in in ob/ob mice resulted in 76.6 ± 2.13% reduction in food specific activities of both leptin proteins. The simplest intake within 24 h after the single tail vein injection, interpretation of the data is that differences are related whereas daily rh-leptin administration resulted in a to sustained in vivo leptin synthesis from Ad-leptin, verreduction of only 43.8 ± 1.5%, compared with controls.
sus rapid clearance of rh-leptin protein administered Lean mice treated with Ad-h-leptin or Ad-m-leptin daily. also had a significantly greater weight reduction by 1 week after treatment, compared with mice injected Multiple daily rh-leptin treatment daily with rh-leptin at 1 mg/kg (an equivalent dose to
In an attempt to achieve a steady-state bioavailability of that received by the ob/ob mice) ( Table 1) . Maximum rh-leptin, we administered rh-protein three times daily at weight losses measured in lean mice treated with Ad-h-5 g per injection (0.05 mg/kg, n = 3), 10 g per injection leptin, Ad-m-leptin, and rh-leptin were 9.6 ± 0.9, (0.1 mg/kg, n = 3), or 50 g per injection (1.0 mg/kg, n 13.0 ± 1.6 and 8.1 ± 0.54%, respectively. These values = 3) ( Figure 4 ). Single (qD) and triple (TID) daily treatwere achieved at 6.5 ± 0.3, 8.7 ± 2.4 and 13.2 ± 3.2 days ments (8 h apart) were, as expected, associated with a following each respective treatment. Weight loss was not dose-dependent response. Only the highest triple dose detected in any of the treatment groups beyond the initial (50 g per injection, total 150 g per mouse daily) was acute response, even in the rh-leptin-treated group, associated with weight loss approaching that observed despite continuation of the daily injections. In the lean with the single Ad-leptin treatment. At this juncture, it treated mice, food intake was reduced transiently by 50 is important to mention that the single 50 g daily dose and 30% for approximately 1 week, starting at 24 h folwas also given to groups of ob/ob mice (n = 3) at three lowing Ad-leptin and rh-leptin treatments, respectively. independent time-points, (7:30 a.m., 3:30 p.m. and 11:30 p.m.). All three treatment regimens resulted in similar Plasma leptin levels Body weight reductions were associated with increased rates of weight loss, excluding any time-dependent effect of rh-leptin treatment relative to the light cycle. serum leptin levels in Ad-leptin- (Figure 2a and b) and rh-leptin-treated ob/ob and lean mice, compared with controls. The minimum effective leptin concentrations Anti-leptin specific antibodies Previous studies in conjunction with adenoviral gene measured for the Ad-h-leptin-and Ad-m-leptin-treated ob/ob mice were 3.9 ± 0.4 and 5.3 ± 0.7 ng/ml, respectdelivery have suggested immune responses against the transgene as a cause for the short-lived gene expression ively. In the ob/ob group, leptin levels peaked during the first week (day 4 ± 1) of Ad-h-leptin and Ad-m-leptin and limited efficacy. 23 We therefore measured antibody levels against both mouse and human leptin in all treattreatment to 22.9 ± 2.6 and 48.9 ± 11.5 ng/ml, respectively. Serum leptin concentrations were 10-to 20-fold ment groups, as well as antibodies against the adenoviral vector. Antibodies were not detected against either Ad-hlower for the endogenously secreted Ad-leptin, compared with rh-leptin which was delivered daily at 1 leptin or Ad-m-leptin in any of the ob/ob or lean treated reliable and reproducible. In this study, we compared the Other contributing factors may be the differences Ad-m-leptin) and rh-leptin.
between Ad-leptin and rh-leptin in the rate of onset of b All leptin-treated groups showed significant weight loss comincreased activity (4 versus 11 days after treatment), and pared with their associated control group.
degree of satiety (approximately 75% of control for 2 weeks versus approximately 45% of control sustained throughout the treatment period). In addition, anti-leptin animals, up to 32 days after treatment. However, leptinantibodies were detected in the sera of animals treated specific antibodies were detected in all ob/ob and lean with the recombinant human leptin protein but not in the mice treated with rh-leptin ( Table 2) . As expected, the sera of animals treated with adenoviral vectors expressadenoviral vector itself mounted high adenovirusing either mouse or human leptin. The raised antibody specific antibody titers (data not shown).
titer against leptin may have interfered with the protein's bioavailability, thus contributing to the differences Enhanced activity and phenotypic correction between the Ad-leptin-and rh-leptin-treated mice. The Noticeable enhancement of physical activity was detected duration during which the antibody response was measwithin 4 days after treatment in the Ad-leptin-treated ured was only up to 32 days after treatment. This may ob/ob mice, in association with their rapid weight loss.
not have been enough time for the generation of antiSimilar enhancement in activity was detected in the rhbodies against the low levels of leptin secreted by the leptin-treated animals by day 11 of the daily protein adenoviral vectors, and it may be that at later dates antiadministrations. This increased activity was captured by bodies would be detected. However, in the case of rhtime-lapse photography; representative sections were leptin, the amount of delivered protein was large and analyzed as described in Materials and methods. The there was a boost on a daily basis which may have conob/ob treated mice were 20-50% more active than ob/ob tributed to the humoral response. Furthermore, the rhcontrol mice during both dark and light cycles. The leptin is an in vitro generated protein; unfolding of a perincreased activity was also accompanied by phenotypic centage of that protein is not an unexpected phenochanges, in that the ob/ob Ad-leptin-treated mice were menon, exposure of antigenic epitopes that are otherwise visibly thinner than ob/ob controls within 10 days after not exposed in a properly folded protein may have also treatment ( Figure 5 ).
contributed to the antigenicity of rh-leptin. In lean mice, the maximum effect of rh-leptin treatment was only 8% Plasma glucose levels reduction in body weight at around 13 days following It has been shown previously that leptin treatment treatment versus 10-13% reduction in Ad-leptin-treated of ob/ob mice results in normalization of glucose groups, reached at 7-9 days. Weight loss was associated levels. 12, [15] [16] [17] [18] We therefore measured plasma glucose levwith 50 versus 30% reduction in food intake in Ad-leptinels following the various treatments of the ob/ob and and rh-leptin-treated groups, respectively. lean mice. Glucose reached normal control levels by days
The findings of this study suggest potential advantages 4 and 7 following Ad-leptin and rh-leptin treatment, of in vivo sustained leptin gene expression over bolus respectively (Figure 6a and b) . recombinant protein therapy. Multiple administrations of In lean animals, neither treatment with Ad-leptin nor rh-leptin per day approached the Ad-leptin-mediated daily injection of rh-leptin with sustained high serum lepefficacy with regard to rate of weight loss. Cohen et al 26 tin levels for 44 days affected blood glucose levels ( Figure  suggested that Escherichia coli-derived leptin may be less 6c). Post-treatment serum glucose levels remained potent than native leptin. They reported no post-transunchanged and indistinguishable from control levels, lational modifications or apparent differences between although both treatments were associated with acute human endogenous leptin and recombinant leptin, weight loss and satiety.
although large doses of the latter are required for induction of weight loss. This study clearly points out the Discussion advantages of continuous low-dose circulation of leptin, with the minimum effective dose found to be 3.9 ± 0.4 For gene therapy to be a viable option for treatment of and 5.3 ± 0.7 ng/ml for the Ad-h-leptin-and Ad-m-lepany specific disorder, it is essential to prove that the tin-treated ob/ob mice, respectively. Thus, if recombinant advantages of gene delivery surpass those of conventional current therapies. The approach must be safe, leptin is to be used as a potential treatment for obesity, the protein versus intermittent administration.
COS cells (Ad-h-leptin), or control. Samples underwent three five-fold serial dilutions with leptin activity and the concentration was determined
It has been shown that leptin treatment of ob/ob mice activity was observed earlier in the Ad-leptin-than in the rh-leptin-treated mice (4 versus 11 days after treatment). High blood glucose levels in ob/ob mice are reduced after leptin treatment. 12, [15] [16] [17] [18] In this study, normalization of blood glucose levels in the ob/ob leptin-treated mice preceded the maximum weight loss, and occurred within the first few days after treatment. However, glucose levels were not affected in lean mice, despite the acute effect of leptin on both weight reduction and food intake, and regardless of whether delivery was by Ad-leptin transi- intake or body weight, and suggested a direct effect of leptin on metabolism. Several groups have suggested that the limited persistbinant adenoviral vector is devoid of all viral coding genes. 29, 30 This new system has the theoretical advantage ence with adenoviral vectors is mainly a function of the immunogenicity of adenoviral proteins. 23, 27 However, of eliminating possible viral protein-mediated immunogenicity. Factors contributing to lack of persistence will more recent data show that the expressed transgene carried by the adenoviral vector is the major immunogen. 28 be addressed in our forthcoming studies.
Figure 4 Comparison of multiple rh-leptin daily injections with a single
The greater efficacy of Ad-leptin compared with rh-lepTo test the latter observations, we used adenoviral vectors expressing either mouse or human leptin. Our results tin is evident in this study, and it remains necessary to identify all the underlying causes of this discrepancy in show that neither protein in the context of the adenoviral vector persisted. The ob/ob mouse model is not ideal for potency. We conclude from these results that maintaining a low level of continuous leptin expression is superior addressing the question of transgene immunogenicity, since the leptin deficiency is almost complete. The lean to pulsed doses in achieving a better therapeutic effect, whether this is achieved by gene delivery, multiple injecmice, on the other hand, do express endogenous leptin, and treatment was associated with a pattern of transient tions, or slow release of recombinant protein. With further improvements in gene delivery vectors, gene expression identical to that observed in the ob/ob mice. Furthermore, persistence was not observed by altering therapy will become the new therapeutic intervention approach that has particular promise for hormone and the route of delivery (intramuscularly versus intravenously (i.v.), data not shown). In all treatment groups, cytokine replacement. cellular infiltrates were detected in target organs (liver and muscle, data not shown). Antibodies against rh-leptin were detected in both the ob/ob and lean treated aniMaterials and methods mals but were not detected in any of the Ad-leptintreated mice. With regards to Ad-vector immunogenicity, other factors such as purification procedures, titers used, Adenoviral vectors Construction of AdHCMVmOb (Ad-m-leptin), AdHCreplication-competent contaminant virus, and viral protein and transgene immunogenicity, may play modulatMVhOb (Ad-h-leptin), and AdHCMVsp1LacZ (Ad-␤gal) recombinant vectors has been described previously, 19 ing roles. The utility of adenovirus-mediated gene delivery has with the exception of replacing lacZ with polymerase chain reaction-generated cDNA inserts of mouse leptin several limitations related to immunogenic response and longevity of expression. We are currently utilizing the (mOb) or human leptin (hOb). Vectors were propagated and titrated as described by Graham and Prevec. 31, 32 adenoviral helper-dependent system in which the recom- Recombinant leptin protein were selected for and maintained in selective medium (growth medium supplemented with 500 g/ml G418 Human leptin was expressed in E. coli, purified from inclusion bodies, and refolded essentially as described.
33
(Geneticin; Gibco/BRL) ). Cells were transfected with human ob receptor isoform b (hOB-Rb), pAH32, and Larger scale refolding was achieved by utilizing an Amicon spiral-wound membrane cartridge (Amicon, pSV2neo at a ratio of 4:4:1 using lipofectamine (Gibco/BRL) following the manufacturer's protocol. At Beverly, MA, USA) instead of dialysis membranes for buffer exchange.
24 h following transfection, stable clones were isolated in selective medium. One of the clones obtained, 293-Ob2, displayed the greatest leptin-induced luciferase activity Cell culture and was used for all analysis. COS cell-generated leptin: COS cells (transformed monkey kidney cell line, from American Type Culture CollecLeptin in vitro functional assay tion (ATCC), Rockville, MD, USA) were maintained in Dulbecco's modified minimum Eagle's medium (DMEM;
Plasmids: The expression vector encoding the hOB-Rb isoform, and the leptin-activated firefly luciferase cDNA Gibco/BRL, Gaithersburg, MD, USA). Media were supplemented with 10% heat-inactivated newborn calf serum reporter construct, pAH32, have been described previously. cell-conditioned media were serially diluted in Opti-MEM, 0.5% BSA. Media were aspirated 6 h after treatwere maintained in growth medium (DMEM, 10% fetal bovine calf serum (Gibco/BRL), 50 mg/ml streptomycin, ment and cells were lysed with 20 l of Promega cell lysis reagent (Promega, Madison, WI, USA). Luciferase assays and 50 U/ml penicillin (Gibco/BRL) ) at 37°C in an atmosphere of 95% air, 5% CO 2 . Stably transfected cells were performed as previously described using Promega luciferase assay reagent. 33 Leptin concentrations were Physical activity ob/ob Mice treated with Ad-m-leptin (n = 5), Ad-h-leptin determined using a human leptin RIA (Linco Research, St Charles, MO, USA).
(n = 5), or Ad-␤gal (n = 5) were videotaped for time-lapse photography at 1 week after treatment. Videotape time Mouse colony intervals were 2 and 4 continuous h during the photoHomozygous ob/ob and lean (ob/?, phenotypically and scoto-phases of the light cycle, respectively. The normal) female mice were purchased from Jackson Labnumber of movements for each individual animal were oratories (Bar Harbor, ME, USA) and maintained for use counted per video field (field = 1/60 of a second). Estiin this study as described. 12 Animals were free of all commated relative activity was calculated for 9-and 11-min mon murine pathogens. Twelve-week-old mice (ob/ob representative shots from the photophase and scotoapproximately 50 g and lean approximately 22 g) were phase, respectively. redistributed based on equal representation of weight per treatment group and caged in groups of five on day 0, Statistics immediately preceding treatment. After a series of basePair-wise comparisons between treatments were made line blood samples were obtained by tail incision from using the two-sample Student's t test and confirmed by conscious mice, animals were treated by tail vein injecthe Wilcoxon rank sum test. Values are reported as mean tion of a single 400 l aliquot of 1 × 10 9 p.f.u. Ad-m-lepvalues ± standard error of the mean (s.e.m.), unless noted tin, Ad-h-leptin, Ad-␤gal, or dialysis buffer, or by i.p.
otherwise. All P values given are two-sided. For injection of 1 g/g (in 200 l) of recombinant leptin promeasurements of leptin that were reported by the Linco tein or vehicle. Animals (ob/ob and lean) were divided Research Laboratory as below a limit, the limit reported into the following six treatment groups: i.v. injection (Adwas used as the value of the observation (eg Ͻ0.1 = 0.1) m-leptin (n = 10), Ad-h-leptin (n = 10) and control Adin all calculations. ␤gal (n = 5) or dialysis buffer (n = 5)), and i.p. injection (recombinant protein (n = 10) and vehicle (n = 5) ). Body weight and food intake were measured daily and blood
